Simple Summary In this review, we examined relevant clinical trial results with immune
checkpoint inhibitors in patients with metastatic urothelial cancer. We also focused on the …

Abstract PD-1/PD-L1 blockade therapy is a promising cancer treatment strategy, which has
revolutionized the treatment landscape of malignancies. Over the last decade, PD-1/PD-L1 …

Background Platinum-based chemotherapy is standard-of-care first-line treatment for
advanced urothelial carcinoma. However, progression-free survival and overall survival are …

Immune checkpoint inhibitor therapies targeting PD‐1/PD‐L1 are now the standard of care
in oncology across several hematologic and solid tumor types, including triple negative …

Abstract Five programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors
are currently approved for treatment of locally advanced or metastatic urothelial carcinoma …

Muscle-invasive bladder cancer (MIBC) represents approximately two-thirds of invasive
urothelial bladder cancers (UBC) and has high morbidity and mortality. Men are over 3-fold …

Immunotherapy, based on immune checkpoint inhibitors (ICIs) targeting the programmed
cell death ligand 1 (PD-L1) and/or programmed death receptor 1 (PD-1), has substantially …

Triple-negative breast cancer (TNBC) accounts for approximately 12% to 17% of all breast
cancers and has an aggressive clinical behavior. Increased tumor-infiltrating lymphocyte …

Background The value of programmed cell death ligand-1 (PD-L1) to predict durable
responses to immune checkpoint inhibitors (ICIs) in metastatic urothelial carcinoma (mUC) is …

Background Assessment of the immune status of muscle-invasive bladder cancer (MIBC)
has previously shown to be prognostically relevant after treatment with curative intent. We …